ALSUntangled No. 52: Glutathione

References

• ALSUntangled [online]. Available at: http://www.alsuntangled.com/open.php. Accessed October 19, 2019.
   Google Scholar
• Wikipedia page on glutathione [online]. Available at: https://en.wikipedia.org/wiki/Glutathione. Accessed October 19, 2019.
   Google Scholar
• Examine page on glutathione [online]. Available at: https://examine.com/supplements/glutathione/. Accessed October 20, 2019.
   Google Scholar
• IV Vitamin Therapy Clinic [online]. Available at: https://www.myvitamintherapy.com. Accessed October 20, 2019.
   Google Scholar
• ALS Worldwide [online]. https://alsworldwide.org/care-and-support/article/glutathione-improves-limb-strength. Accessed October 20, 2019.
   Google Scholar
• Ross E, Winter A, Wilkins H, Sumner W, Duval N, Patterson D, et. al. A cysteine-rich whey supplement (Immunocal) delays disease onset and prevents spinal cord glutathione depletions in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Antioxidants 2014;3:843–65.
   Google Scholar
• Shahripour R, Harrigan M, Alexandrov A. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav. 2014;4:108–22.
   PubMed Web of Science ®Google Scholar
• Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules 2019; 24:1583.
   PubMed Web of Science ®Google Scholar
• Pollari E, Goldsteins G, Bart G, Koisinaho J, Giniatullin R. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front Cell Neurosci 2014;8:131.
   PubMed Web of Science ®Google Scholar
• Barber S, Shaw P. Oxidative Stress in ALS: key role in motor neuron injury and therapeutic target. Free Radi Biol Med.2010;48:629–41.
   PubMed Web of Science ®Google Scholar
• Orrell R, Lane R, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler.2008;9:195–211.
   PubMed Web of Science ®Google Scholar
• Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505–12.
   PubMed Web of Science ®Google Scholar
• Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, et. al. Panel of oxidative stress and inflammatory biomarkers in ALS: a pilot study. Can J Neurol Sci. 2017;44:90–5.
   PubMed Web of Science ®Google Scholar
• Toghi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett.1999;260:204–6.
   PubMed Web of Science ®Google Scholar
• Choi Y, Lee P, Statland J, McVey A, Dimachkie M, Brooks W, et. al. Reduction in cerebral antioxidant, glutathione (GSH), in patients with ALS: a preliminary study. Neurology 2015;84:14.
   Google Scholar
• Weiduschat N, Mao X, Hupf J, Armstrong N, Kang G, Lange D, et. al. Motor cortex glutathione deficit in ALS measured in vivo with the j-editing technique. Neurosci Lett.2014;570:102–7.
   PubMed Web of Science ®Google Scholar
• Cova E, Bongioanni P, Cereda C, Metelli MR, Salvaneschi L, Bernuzzi S, et. al. Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients. Neurochem Int.2010;56:687–93.
   PubMed Web of Science ®Google Scholar
• Chen T, Turner BJ, Beart PM, Sheehan-Hennessy L, Elekwachi C, Muyderman H. Glutathione monoethyl ester prevents TDP-43 pathology in motor neuronal NSC-34 cells. Neurochem Int.2018;112:278–87.
   PubMed Web of Science ®Google Scholar
• Andreassen O, Dedeoglu A, Klivenyi P, Beal M, Bush A. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 2000;11:2491–3.
   PubMed Web of Science ®Google Scholar
• Henderson J, Javaheri M, Kopko S, Roder J. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. J Neurosci. 1996;16:7574–82.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Pastusza KA, Sapp PC, Mathews RK, Leahy J, Pasinelli P, et. al. Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity. Neurology 2002;59:729–34.
   PubMed Web of Science ®Google Scholar
• Ludolph A, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler J, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11:38–45.
   PubMed Web of Science ®Google Scholar
• PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/treatment/glutathione. Accessed October 31, 2019.
   Google Scholar
• PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/treatment/immunocal. Accessed October 31, 2019.
   Google Scholar
• PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/treatment/n-acetylcysteine-nac. Accessed October 31, 2019.
   Google Scholar
• Harrison D, Mehta P, van Es M, Stommel E, Drory V, Nefussy B, et. al. ALS reversals: demographics, disease characteristics, treatments, and co-morbidities. Amyotrophic Lateral Scler Frontotemporal Degener. 2018;19:495–9.
   PubMed Web of Science ®Google Scholar
• Mangelsdorf I, Walach H, Mutter J. Healing of amyotrophic lateral sclerosis: a case report. Complement Med Res. 2017;24:175–81.
   PubMed Web of Science ®Google Scholar
• Chio A, Cucatto A, Terreni A, Schiffer D. Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial. Ital J Neuro Sci. 1998;1:363–6.
   Google Scholar
• Louwerse E, Weverling G, Bossuyt P, Meyjes F, de Jong J. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol. 1995;52:559.
   PubMed Web of Science ®Google Scholar
• Witschi A, Reddy S, Stofer B, Lauterburg B. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43:667–9.
   PubMed Web of Science ®Google Scholar
• Allen J, Bradley R. Effects of oral glutathione on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17:827–33.
   PubMed Web of Science ®Google Scholar
• Hwang P, Morales Marroquín FE, Gann J, Andre T, McKinley-Barnard S, Kim C, et. al. Eight weeks of resistance training in conjunction with glutathione and L-cirtulline supplementation increases lean mass and has no adverse effects on blood clinical safety markers in resistance-trained males. J Int Soc Sports Nutr. 2018;15:30.
   PubMed Web of Science ®Google Scholar
• Hauser R, Lyons K, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord. 2009;24:979–83.
   PubMed Web of Science ®Google Scholar
• Mischley L, Lau R, Shankland E, Wilbur T, Padowski J. Phase IIb study of intranasal glutathione in Parkinsons disease. J Parkinsons Dis. 2017;7:289–99.
   PubMedGoogle Scholar
• Honda Y, Kessoku T, Sumida Y, Kobayashi T, Kato T, Ogawa Y, et. al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17:96.
   PubMed Web of Science ®Google Scholar
• Davids LM, Van Wyk JC, Khumalo NP. Intravenous glutathione for skin lightening: inadequate safety data. S Afr Med J. 2016;106:782–6.
   PubMedGoogle Scholar
• Prousky J. The treatment of pulmonary diseases and respiratory-related conditions with inhaled (nebulized or aerosolized) glutathione. Evid Based. Complement Alternat Med. 2008;5:27–35.
   PubMed Web of Science ®Google Scholar
• Millea P. N-acetylcysteine: multiple clinical applications. Am Fam Physician 2009;80:265–9.
   PubMed Web of Science ®Google Scholar